Proton-coupled folate/antifolate transport

描述（由申请人提供）：本申请建立在该实验室发现的质子偶联叶酸转运蛋白（PCFT）之上，PCFT是一种低ph转运蛋白，对新一代抗叶酸药物培美曲塞具有高亲和力，当主要叶酸/抗叶酸转运蛋白（减少的叶酸载体）缺失和肿瘤细胞缺失时，这种转运蛋白能唯一地维持该药物的活性

DESCRIPTION (provided by applicant): This application builds upon this laboratory's discovery of the proton-coupled folate transporter (PCFT), a low-pH transporter with high affinity for the new-generation antifolate, pemetrexed, that uniquely sustains the activity of this agent when the major folate/antifolate transporter, the reduced folate carrier, is absent and tumor cells are highly resistance to methotrexate and other antifolates. Studies over the current funding period have begun to elucidate the structure-function of PCFT encompassing its topology, residues required for its function, and elements that discriminate among folates/antifolates. The studies proposed are focused on developing a comprehensive understanding of the structural basis for PCFT function combining laboratory and computational strategies. The specific aims are: (i) To identify residues that define the aqueous translocation pathway, that define folate binding and its specificity, and that are determinants of proton binding and coupling. These studies utilize the substituted cysteine accessibility method. (ii) To characterize the interaction between PCFT transmembrane helices that are determinants of tertiary structure, and an extracellular gate, by chemical cross-linking of di-cysteine mutants, and to clarify the basis for the role the first intracellular loop plays in PCFT function. (iii) To determine the impact of structural alterations of PCFT on the antitumor activities of pemetrexed and other antifolates in vitro, particularly under acidic conditions. (iv) To utilize the experimental data obtained, in an iterative approach, to inform, refine and validate a homology model of PCFT and to undertake docking analyses in order to identify elements critical to the avidity and selectivity of the folate/antifolate binding pocket. These studies will also inform the development of novel antifolates designed for selectively delivery by PCFT within the acidic microenvironment of solid tumors. Mutant PCFTs developed in these studies are assessed for their stability, trafficking to the cell membrane, folate/antifolate substrate selectivity, and roles in proton binding and proton coupling by transfection into a unique Hela cell line that lacks endogenous folate transporters. This is complemented by electrophysiological measurements in Xenopus oocytes of current and acidification generated by the transport of the folate-proton-PCFT ternary complex, that also make possible analyses of transport properties of antifolates that are not radiolabled.